- Monoclonal
antibodies(mAbs) are just like antibodies except they are artificially
produced from the clones of a single cell.
- Monoclonal
antibodies are made by multiple, identical copies (i.e. clones) of a
cell called a hybridoma.
- Monoclonal
antibodies are produced by fusing single antibody-forming cells to tumor
cells grown in culture. The resulting cell is called a
hybridoma.
- Monoclonal
antibodies are created with cell fusion technology and cell culture
technology .
- Once a monoclonal
antibody is made, it can be used as a specific probe to track down and
purify the specific protein that induced its formation.
- Monoclonal
antibodies can be used to classify strains of a single pathogen, e.g.
Neisseria gonorrhoeae can be typed using monoclonal
antibodies.
- Monoclonal
antibodies are widely used as diagnostic and research reagents. Their
introduction into human therapy has been much slower.
- Monoclonal
antibodies (MABs or MOABs) work on cancer cells in the same way natural
antibodies work, by identifying and binding to the target
cells.
- The market for
therapeutic monoclonal antibodies (mAbs) is one of the most dynamic
sectors within the pharmaceutical industry.
- The current global
clinical antibody pipeline, which comprises 132 products in development
and is dominated by humanized (42%) and fully human (28%)mAbs, is poised
to deliver as many as 16 new products between 2004 and 2008.
- As a result of
growth in existing markets for mAb therapeutics,and the opening of new
ones, the global market is projected to increase to US $16.7 billion in
2008.
- The mAbs market is
expected to almost triple in value over the next six years from $10.3
billion in 2004 to $30.3 billion. Oncology products will continue to
dominate the market. However, sales of arthritis, immune and
inflammatory disorders (AIID) products are forecast to grow strongly and
account for 40.1% of the market by 2010.
- Chimeric mAbs were
the undisputed leaders,with 43% growth and US $3.8 billion in sales,
followed by humanized
mAbs with more than US $1.4 billion in sales
and growth of 29%.
- The development
focus of the industry is moving away from murine and chimeric
antibodies, to humanized and, in particular, fully human technologies. A
wave of fully human products are expected to launch from 2007 onwards,
accounting for 12 of the 20 launches between 2007 and 2010.
- Roche and
Genentech dominate the mAbs market, with a combined market share of
44.9% in 2004, although this is forecast to slip to 35.7% in 2010.
- Next generation
antibodies are forecast to drive the market towards the $30 billion mark
by 2011 due to a high level of innovation in early-stage discovery and
several potential nichebusters set to launch in the next 5
years.
- Applications of
Monoclonal Antibodies include: Identification of Cell Surface Markers ,
Detection Assays , Purification Techniques , Gene Identification ,
Disease Therapy , Use in Applied Chemistry
Entrepreneur who
want the information can E-Mail us to
informer@eth.net,
primaryinfo@gmail.com |